Advanced breast cancer in post-menopausal women. Adjuvant treatment of post-menopausal women w/ hormone receptor +ve early invasive breast cancer & in early breast cancer hormone receptor +ve post-menopausal woman who have received 2-3 yr of adjuvant tamoxifen.
Adult including elderly 1 mg once daily. Postmenopausal women w/ hormone receptor-positive early invasive breast cancer Recommended duration of adjuvant endocrine treatment: 5 yr.
Not to be used in pre-menopausal women. Avoid concomitant use w/ tamoxifen or estrogen-containing therapies. Increased risk of fracture due to reduction in bone mineral density. Carefully monitor & initiate treatment or prophylaxis for osteoporosis. Moderate or severe hepatic & severe renal impairment. Do not use in boys w/ growth hormone deficiency in addition to growth hormone treatment. May impair the ability to drive & use machinery. Childn & adolescents.
Sign Out
